FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171937401> ?p ?o ?g. }

• W2171937401 endingPage "4477" @default.
• W2171937401 startingPage "4467" @default.
• W2171937401 abstract "Article15 August 2001free access Identification of a mammalian H+-myo-inositol symporter expressed predominantly in the brain Marc Uldry Marc Uldry Institute of Pharmacology and Toxicology, University of Lausanne, Lausanne, Switzerland Search for more papers by this author Mark Ibberson Mark Ibberson Institute of Pharmacology and Toxicology, University of Lausanne, Lausanne, Switzerland Search for more papers by this author Jean-Daniel Horisberger Jean-Daniel Horisberger Institute of Pharmacology and Toxicology, University of Lausanne, Lausanne, Switzerland Search for more papers by this author Jean-Yves Chatton Jean-Yves Chatton Institute of Physiology, University of Lausanne, Lausanne, Switzerland Search for more papers by this author Beat M. Riederer Beat M. Riederer Institute of Cell Biology and Morphology, University of Lausanne, Lausanne, Switzerland Search for more papers by this author Bernard Thorens Corresponding Author Bernard Thorens Institute of Pharmacology and Toxicology, University of Lausanne, Lausanne, Switzerland Search for more papers by this author Marc Uldry Marc Uldry Institute of Pharmacology and Toxicology, University of Lausanne, Lausanne, Switzerland Search for more papers by this author Mark Ibberson Mark Ibberson Institute of Pharmacology and Toxicology, University of Lausanne, Lausanne, Switzerland Search for more papers by this author Jean-Daniel Horisberger Jean-Daniel Horisberger Institute of Pharmacology and Toxicology, University of Lausanne, Lausanne, Switzerland Search for more papers by this author Jean-Yves Chatton Jean-Yves Chatton Institute of Physiology, University of Lausanne, Lausanne, Switzerland Search for more papers by this author Beat M. Riederer Beat M. Riederer Institute of Cell Biology and Morphology, University of Lausanne, Lausanne, Switzerland Search for more papers by this author Bernard Thorens Corresponding Author Bernard Thorens Institute of Pharmacology and Toxicology, University of Lausanne, Lausanne, Switzerland Search for more papers by this author Author Information Marc Uldry1, Mark Ibberson1, Jean-Daniel Horisberger1, Jean-Yves Chatton2, Beat M. Riederer3 and Bernard Thorens 1 1Institute of Pharmacology and Toxicology, University of Lausanne, Lausanne, Switzerland 2Institute of Physiology, University of Lausanne, Lausanne, Switzerland 3Institute of Cell Biology and Morphology, University of Lausanne, Lausanne, Switzerland *Corresponding author. E-mail: [email protected] The EMBO Journal (2001)20:4467-4477https://doi.org/10.1093/emboj/20.16.4467 PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Inositol and its phosphorylated derivatives play a major role in brain function, either as osmolytes, second messengers or regulators of vesicle endo- and exocytosis. Here we describe the identification and functional characterization of a novel H+-myo- inositol co-transporter, HMIT, expressed predominantly in the brain. HMIT cDNA encodes a 618 amino acid polypeptide with 12 predicted transmembrane domains. Functional expression of HMIT in Xenopus oocytes showed that transport activity was specific for myo-inositol and related stereoisomers with a Michaelis–Menten constant of ∼100 μM, and that transport activity was strongly stimulated by decreasing pH. Electrophysiological measurements revealed that transport was electrogenic with a maximal transport activity reached at pH 5.0. In rat brain membrane preparations, HMIT appeared as a 75–90 kDa protein that could be converted to a 67 kDa band upon enzymatic deglycosylation. Immunofluorescence microscopy analysis showed HMIT expression in glial cells and some neurons. These data provide the first characterization of a mammalian H+-coupled myo- inositol transporter. Predominant central expression of HMIT suggests that it has a key role in the control of myo-inositol brain metabolism. Introduction Myo-inositol is a crucial constituent of living cells and participates in several physiological functions. It is a major osmolyte and also serves as the precursor to phosphatidylinositol (PtdIns), the major inositol-containing phospholipid. Phosphorylation of the inositol hydroxyl groups at position 3, 4 or 5 results in a large number of different phospholipid species with specific functions. Phosphat idylinositol-4,5-bisphophate (PtdIns-4,5-P2) can be hydrolysed by phospholipase C to give rise to the second messengers inositol-1,4,5-triphosphate (IP3) and diacylglycerol. Activation of IP3 kinase by different signalling pathways (Cheatham and Kahn, 1995; Atwal et al., 2000; Kaplan and Miller, 2000) can produce PtdIns-3,4-P2 or PtdIns-3,4,5-P3. These are ligands for pleckstrin homology (PH) domain-containing proteins such as the protein kinases PDK1 or Akt/PKB (Irvine, 1998; Jost et al., 1998; Leevers et al., 1999), which are implicated in further propagating intracellular signals. Phosphorylation by phosphoinositide 3-kinase (PI3K) of PtdIns generates PtdIns-3-P, which is a ligand for FYVE domain-containing proteins (Leevers et al., 1999), such as EEA1, an endosomal protein implicated in early endosome fusion (Simonsen et al., 1998). Polyphosphoinositides may interact with the C2B domain of synaptotagmin, an interaction that leads to inhibition of synaptic vesicle exocytosis (Schiavo et al., 1995; Ohara-Imaizumi et al., 1997; Mehrotra et al., 2000). PtdIns, by interacting with AP2 adaptor proteins and the PH domain of the GTPase dynamin, participates in clathrin-coated pit-dependent endocytosis (Gaidarov et al., 1996; Rapoport et al., 1997). Genetic inactivation of synaptojanin 1, a polyphosphoinositide phosphatase present in clathrin-coated pits of neurons, prevents normal dissociation of the clathrin coat and leads to impaired synaptic vesicle re-endocytosis and to synaptic depression (Cremona et al., 1999). Alterations in brain inositol levels are associated with diseases of the central nervous system. For instance, the neurological dysfunction characteristic of Down syndrome is correlated with an increase in brain inositol. This may be caused by the presence of three copies of the Na+-myo-inositol transporter gene, which is located on chromosome 21 (Shetty et al., 1995; Berry et al., 1999). On the other hand, effective treatment of bipolar disorders with lithium salt is hypothesized to result from interference with inositol metabolism. Indeed, both inositol monophosphate phosphatase and polyphosphoinositide 1-phosphate phosphatase are inhibited by Li+. This inhibition causes an impairment of inositol recycling following stimulation of the IP3 cycle by activated Gq protein-coupled receptors, thereby reducing the cellular availability of inositol for further signal transduction processes (Berridge et al., 1989; Williams and Harwood, 2000). Cellular myo-inositol can originate from three sources: recycling of inositol phosphate second messengers, synthesis from glucose or uptake of extracellular inositol. Transport of myo-inositol across the cellular membrane requires the presence of a specific transporter. So far, a single mammalian inositol transporter has been identified. This is a Na+-coupled transporter, SMIT, which is expressed in the kidney cortex and medulla, and in the brain (Kwon et al., 1992). Its expression is increased by hypertonicity, through a mechanism controlled by the tonicity-sensitive transcription factor TonEBP (Miyakawa et al., 1999). Very high levels of expression can be obtained in different brain areas when plasma osmolality is increased. SMIT, therefore, appears to be primarily involved in a protective response to high tonicity. Here we report on the structural and functional characterization of a novel mammalian inositol transporter. This was identified by screening databases for glucose transporter-related sequences. We demonstrate, however, that this new molecule does not transport glucose or related hexoses, but is a H+-myo-inositol symporter (HMIT). It is predominantly expressed in the brain and detected both in astrocytes and neurons. HMIT may be involved in specific aspects of brain inositol metabolism that play critical roles in intracellular signalling pathways and synaptic or other vesicle traffic. Results Structure of HMIT The public expressed sequence tag (EST) database was screened using the GlutX1 (or GLUT8) amino acid sequence (Ibberson et al., 2000). This led to the identification of several homologous sequences, among which was a new rat EST clone (DDBJ/EMBL/GenBank accession No. AI576033) isolated from a spleen cDNA library that we refer to as HMIT. A 300 bp fragment of this clone was amplified by RT–PCR from rat spleen total RNA and used to screen a northern blot of different tissue RNAs. The highest expression of the corresponding mRNA was found in brain and hypothalamus (see below). Full-length cDNAs were then isolated from rat hypothalamus and human frontal cortex cDNA libraries. The rat sequence is 618 amino acids long and the human sequence has 629 amino acids. These sequences are 90% identical and 93% homologous to each other (DDBJ/EMBL/GenBank accession Nos: rat HMIT, AJ315643; human HMIT, AJ315644). The rat HMIT sequence is 36% identical and 44% homologous to the rat GlutX1 (Figure 1A). It contains 12 predicted transmembrane domains (TM) with a long cytoplasmic loop between TM6 and TM7 (Figure 1B). Several motifs that have been shown to be important for glucose transport activity in the Glut family are conserved, and are highlighted in Figure 1A. Remark ably, the N-terminal region contains an endoplasmic reticulum (ER) retention signal (RRR) and a dileucine internalization signal. The C-terminal tail contains a tyrosine-based internalization motif, YIRV, of the consensus structure Yxxo (where x is any amino acid and o is a hydrophobic amino acid). An extracellular loop of 95 amino acids, which contains three N-glycosylation sites, is present between TM9 and TM10. Figure 1.HMIT sequence. (A) Alignment of rat GlutX1 and ratHMIT amino acids sequences using the pileup program (GCG). HMIT internalization motifs (LL and YIRV) and the ER retention motif (RRR) are underlined. The approximate positions of TM domain are marked with boxes. Highly conserved CGFC and cysteine residues in the extracellular loop between TM9 and TM10 are circled. Black shading indicates identical amino acids, grey shading indicates homologous amino acids, ∼, gaps; filled triangle, N-glycosylation sites. (B) Proposed secondary structure of HMIT. The model is based on a hydropathy index obtained by the Tmpred program. Internalization and ER retention motifs, sugar transporter signature GRR, conserved residues in the extracellular loop and putative N-glycosylation sites are highlighted. (C) Phylogenetic tree based on multiple alignments of HMIT with other sugar transporters. The alignments were performed with the pileup program (GCG) and the rectangular cladogram was built using the TreeView program. Proteins of unknown functions are given by their accession number. Download figure Download PowerPoint Figure 1C shows a dendrogram of the sequence relatedness of HMIT and the closest transporter molecules. HMIT shows highest similarity with five non-mammalian proteins of unknown function. Three are from Caeno rhabditis elegans and two from Arabidopsis thaliana. These five proteins contain an extracellular loop between TM9 and TM10, which shows an average of 33% homology and 30% identity with HMIT's loop. The loops of these six proteins all contain eight cysteines, a CGFC motif and 2–4 N-glycosylation sites. The dendrogram further shows that other closely related proteins include the bacterial H+-galactose and H+-xylose symport ers, H+-myo-inositol symporter of Leshmania donovani (MIT) and two yeast inositol transporters (ITR1 and ITR2). Transport activity and surface expression of HMIT and mutants Transport activity was tested by heterologous expression in Xenopus oocytes of HMIT containing a flag epitope at its C-terminal end. The wild-type form of HMIT was not expressed at the cell surface of oocytes, as revealed by immunofluorescence microscopy (Figure 2A). Surface expression could, however, be obtained following mutation, either individually or in combination, of the two putative internalization motifs and the ER retention signal. Mutation of the ER retention signal (mutant 1: RRR4/6AAA) was not sufficient to induce cell surface expression. Mutation of the dileucine motif (mutant 2: LL22/23AA) or of the tyrosine-based motif (mutant 3: YIRV599/602AIRA) induced expression at the plasma membrane at a level similar to that of the double mutants (mut1 + 2) and (mut1 + 3) (Figure 2A). The third double mutants (mut2 + 3) showed stronger expression at the cell surface and the triple mutant (mut1 + 2 + 3) induced maximal plasma membrane expression. All mutants showed similar level of expression in the oocytes, as assessed by intracellular staining, which reflects proteins present in the ER and Golgi network. Similar results were obtained when the different mutants for HMIT were transiently expressed in HEK293T cells and analysed by immunofluorescence microscopy (data not shown). Figure 2.HMIT functional expression in Xenopus oocytes. (A) Immunofluorescence microscopic detection of HMIT expression in oocytes. Oocytes were injected with the RNA coding for different mutated forms of HMIT. Control oocytes were not injected. Insertion of a C-terminal flag sequence allowed immunofluorescence studies using anti-flag antibody. The different HMIT mutants are as follows: mut1, RRR4/7AAA; mut2, LL20/21AA; mut3, YIRV599/602AIRA or different combinations of these mutations. The upper images show expression at the cell surface; the lower images show staining over the oocyte interior and reflect proteins present in the ER and Golgi apparatus, and provide a control for the level of expression of each protein. (B) The same HMIT mutants were tested for the inositol uptake experiment at pH 5.0 or 7.0. Data are the mean ± SD of at least seven oocytes. Statistical significance was compared with non-injected oocytes: *p <0.02; **p <0.002. Download figure Download PowerPoint Transport of hexoses by the oocytes injected with the various mutated forms of HMIT was tested first. As no transport activity could be detected and as HMIT presented sequence homology with inositol transporters, myo-inositol uptake was tested using a concentration of 100 μM at pH 7.0 (Figure 2B). Transport activity was closely correlated with the level of cell surface expression of HMIT. Oocytes injected with HMIT, mut1 or mut2 did not show any significant uptake activity. Uptake by the other mutants (mut3, mut1 + 2, mut1 + 3, mut2 + 3, mut1 + 2 + 3) was significant and was maximal for the triple mutant, which showed a 15-fold increase in transport activity over non-injected oocytes. Remarkably, transport activity was markedly increased by decreasing the pH of the extracellular medium from 7.0 to 5.0. Whereas HMIT- or mut1-injected oocytes still did not transport at the low pH, mutant 2 showed significant transport activity. All other mutants showed an ∼6-fold increase in uptake activity at pH 5.0 compared with pH 7.0. Maximal transport activity was produced by the triple mutant, which showed a 120-fold increase compared with non-injected oocytes. Transport activity was not altered by the insertion of the flag epitope at the C-terminal tail as the same activity was obtained in the presence or absence of this added sequence to the triple mutant. Finally, acidification-dependent myo-inositol uptake could also be demonstrated in HEK293T cells transiently expressing the triple mutant of HMIT. HMIT affinity for inositol was determined at different pH values using oocytes injected with the triple mutant. Kinetic studies revealed that uptake was linear during the first 45 min. For determination of the Michaelis–Menten (Km) constant, uptake experiments were performed with different concentrations of inositol and were stopped after 15 min of incubation. Analysis of the fitted curves indicated a Km for inositol of ∼100 μM, which was not dependent on the pH tested (Figure 3A); the Vmax, however, was strongly increased by decreasing the pH. Transport selectivity was then evaluated, at pH 5.0, by carrying out uptake experiments in the presence of an excess of tested substrates. Figure 3B shows that uptake of radioactive myo-inositol could be competed by a 300-fold excess of unlabelled myo-inositol. Partial competition was also obtained with an excess of scillo-, muco- and chiro-inositol, but not of allo-inositol. None of the hexoses tested (D-glucose, L-glucose, galactose, fructose, mannose, 2-deoxy-glucose, glucosamine or maltose) competed with myo-inositol transport. Transport could be inhibited ∼90% by phloretin, phlorizin or cytochalasin B; lithium chloride had no inhibitory effect. Figure 3.HMIT affinity and specificity for myo-inositol transport. (A) Concentration- and pH-dependence of myo-inositol uptake by oocytes injected with the triple mutant form of HMIT. Myo-inositol concentrations ranged from 25 μM to 5 mM. Data were fitted to the Michaelis–Menten equation. Each value is the mean ± SD of at least 10 oocytes. Km values for myo-inositol transport were ∼100 μM and were identical at the different pH values tested. (B) Effects of competitors and inhibitors on myo-inositol uptake in oocytes injected with the triple mutant form of HMIT. Results are expressed as a percentage of the specific myo-inositol uptake. Inositol stereoisomer concentrations were 100 μM. Competing sugars were added at a concentration of 30 mM, LiCl at 20 mM, phloretin at 300 μM, phlorizin at 5 mM and cytochalasin B at 250 μM. Each value represents the average for 6–10 oocytes. Download figure Download PowerPoint Electrophysiology As shown in Figure 4A, application of 2 mM myo-inositol in a pH 5.0 solution induced an immediate and reversible inward current of ∼50 nA in an oocyte expressing the triple mutant form of HMIT, while it had no effect in a non-injected or water-injected oocyte. Figure 4.Electrophysiological analysis of HMIT transport activity. (A) Original current recording from a Xenopus oocyte expressing HMIT, at a holding potential of −50 mV, and in a pH 5.0 extracellular solution. Addition of 2 mM myo-inositol (In.) induced a reversible inward current in a Na+-containing or a nominally Na+-free solution (no Na). I–V curves were recorded before, during and after each exposure to myo-inositol. (B) I–V curves of the current induced by 2 mM myo-inositol, at pH 5.0, in non-injected oocytes (open symbols, n = 5) and in oocytes expressing HMIT (closed symbols, n = 18). Currents were recorded in Na+-containing solution (circles) and in nominally Na+-free solutions (triangles). In non-injected oocytes, myo-inositol had no significant effect on the holding current at any membrane potential. In oocytes expressing HMIT, an inward current was activated by myo-inositol; the amplitude of this current was slightly (∼15%) smaller in the nominal absence of Na+ that in the presence of 100 mM Na+. (C) I–V curves of the current induced by 2 mM myo-inositol, at pH ranging from 4.0 to 7.5 in oocytes expressing HMIT (n = 7). At all membrane potentials, the amplitude of the current induced by 2 mM myo-inositol increased from practically 0 at pH 7.5 to a maximum at pH 4.0. At high negative membrane potential, there was no increase between pH 5.0 and 4.0, indicating saturation. (D) Quantification of the pH dependence of inositol transport. The best fitting Imax and pKa were obtained by fitting the following equation to the inositol-induced current (Iin) at each potential, using the non-linear fit routine of the Kaleidagraph® program (Synergy Software, Reading, PA): Iin=Imax/10(pH − pKa). Examples of fits are presented for the −110, −50 and 10 mV membrane potentials. (E) The pKa and the Imax calculated for each membrane potential, from the mean current values at the five pH values tested. Both the maximal current and the apparent pKa were voltage sensitive (large maximal currents and lower pKa at negative potentials), with a steeper slope for pKa. Download figure Download PowerPoint A number of small neutral organic molecules are imported into the cell by means of Na-coupled co-transport systems, such as the Na+–glucose co-transporter [the SGLT family (Hediger and Rhoads, 1994)] or the Na+–myo-inositol co-transporter (Kwon et al., 1992). We tested for a possible Na+ dependence of the current induced by myo-inositol in oocytes expressing the triple mutant form of HMIT by comparing the effect of 2 mM myo-inositol in the presence of and in the nominal absence of extracellular Na+ at pH 5.0. As shown in Figure 4B, no significant myo-inositol-induced current could be detected in non-injected oocytes, while large inward currents were induced in oocytes expressing the triple mutant form of HMIT both in the presence and absence of Na+. Even though the myo-inositol-induced currents were slightly smaller in the absence of extracellular Na+, the difference was small and showed a clearly different behaviour from the Na+–myo-inositol co-transporter (Kwon et al., 1992). The current–voltage (I–V) relationship of the myo-inositol-induced current and its pH dependence are shown in Figure 4C. Hardly any myo-inositol-induced current could be detected at pH 7.5, while significant inward currents could be recorded at all lower pH values. There was an increase in current amplitude with lower pH at all potential, but saturation was reached with a pH lower than 5.0 at high negative membrane potential. Fitting the current data to a titration curve at each potential indicated that both the maximal current (Imax) and the apparent pKa were voltage dependent, as indicated in Figure 4D and E. The apparent pKa ranged from ∼6.1 at −130 mV to ∼5.3 at positive membrane potentials. The voltage dependence of the pKa indicated that the proton-binding site is located in the membrane electrical field. An electrical distance of 0.30 can be calculated from the voltage dependence (197 mV/pH unit). Intracellular pH measurements In order to verify that protons are co-transported with myo-inositol, we evaluated whether transport would lead to intracellular acidification. In the first series of experiments, oocytes expressing HMIT were exposed to a pH 5.5 solution in the presence or absence of 2 mM myo-inositol, and intracellular acidification was measured using pH-sensitive microelectrodes. Figure 5A shows a significant myo-inositol-dependent decrease in intracellular pH (pHi) from 7.57 to 7.37 in HMIT-expressing oocytes. No intracellular acidification could be measured in the same conditions in non-injected oocytes. Figure 5.Uptake of myo-inositol induces intracellular acidification. (A) Measurement of intracellular pH in oocytes injected (HMIT) or not (N.I.) with the mRNA for the triple mutant form of HMIT. Oocytes were exposed to a pH 5.5 solution with or without 2 mM myo-inositol prior to pHi measurements. Data are the mean ± SE of at least 11 oocytes. The difference in pHi between HMIT-injected oocytes in the presence and absence of myo-inositol is statistically significant with p <0.002. (B) Intracellular acidification of HEK293T cells expressing HMIT. Cells were exposed to different bath solutions at the indicated pH, and intracellular BCECF fluorescence was recorded. Perifusion of the cells with 2 mM myo-inositol for 2 min (box) induces their acidification. (C) pH dependence of myo-inositol-induced intracellular acidification. NT, non-transfected HEK293T cells; HMIT, HEK293T cells transiently transfected with the HMIT triple mutant. Download figure Download PowerPoint In a second series of tests, acidification of HEK293T transiently transfected with the HMIT triple mutant cDNA was measured by recording the fluorescence of the pH-sensitive dye BCECF-AM [2′,7′-bis(carboxyethyl)-5,6-carboxyfluorescein]. Cells were incubated in solutions fixed at different pH and perfused with the same solution containing 2 mM myo-inositol. Significant acidification, as measured by the fluorescence excitation ratios, was obtained after application of inositol on transfected cells at all pH values tested and was inversely proportional to the pH of the bath solution (Figure 5B). As shown in Figure 5C, no acidification was observed for non-transfected cells whereas myo-inositol-dependent cellular acidification was dependent on a decrease in extracellular pH for cells expressing HMIT. HMIT mRNA and protein analysis Analysis of HMIT mRNA expression in different rat tissues was performed by northern blot analysis. Figure 6 shows that the 4.5 kb HMIT transcript was expressed predominantly in the brain, with high expression found in cerebral cortex, hippocampus, hypothalamus, cerebellum and brainstem. HMIT was detected in RNA prepared from primary cultures of neuronal or glial cells. A low level of expression was detected in white, brown and epididymal adipose tissues, and in kidney. Figure 6.Tissue distribution of HMIT. Northern blot of total RNA from adult rat and mouse tissues. Ten micrograms of total RNA were loaded in each lane. Hybridization with a HMIT cDNA probe reveals a single 4.5 kb transcript, which was at highest abundance in different brain regions. All tissues are of rat origin, except for the mouse total brain lane and for βTc-Tet cells, which are of mouse origin. Download figure Download PowerPoint HMIT expressed in reticulocyte lysates migrates as a 67 kDa protein, exactly at the calculated size of the protein. In the presence of microsomal membranes, the migration is shifted to an apparent size of 76 kDa, compatible with the addition of three N-linked oligosaccharide side chains. This size is the same as that of HMIT expressed in oocytes (Figure 7A). HMIT expressed transiently in HEK293 cells or in brain membranes was identified by western blot analysis using affinity-purified polyclonal rabbit and chicken antibodies raised against the C-terminal cytoplasmic end of the protein (Figure 7B). In membrane protein fractions of HEK293 cells, HMIT migrates as two bands, one centred on 83 kDa and one with an apparent mol. wt of 66–69 kDa. The upper band could be completely converted into the lower 66–69 kDa band upon peptide N-glycosidase F (PNGaseF) deglycosylation. In the brain membrane, only the high molecular weight band was observed, which could be converted into the fast migrating band upon PNGaseF treatment. Figure 7.Characterization of HMIT protein. (A) Left: immuno precipitation of HMIT expressed in oocytes using anti-Flag antibodies; (+) injected oocytes, (−) non-injected oocytes. Right: immunoprecipitation of HMIT synthesized from synthetic RNA in a rabbit reticulocyte lysate in the presence (+) or absence (−) of canine pancreas microsomal membranes. (B) Western blot analysis of HMIT present in membrane proteins from transiently transfected (+) or mock-transfected (−) HEK293T, or in membrane preparations from adultrat brain (Brain), using an anti-HMIT rabbit polyclonal antibody. Membrane proteins were subjected (+) or not (−) to PNGase F treatment prior to electrophoretic separation. Download figure Download PowerPoint Immunolocalization of HMIT Immunofluorescence microscopy using affinity-purified antibodies was used to study HMIT brain localization. Figure 8A and B shows immunofluorescence microscopy localization of HMIT in astrocytes of the hippocampus and in neurons of the cortex. Subcellular localization of HMIT was finally assessed by immunoelectron microscopy. Expression of the co-transporter in an astrocytic glial endfoot is presented in Figure 8C, and shows staining present inside the cell and also with the plasma membrane. Figure 8.Immunolocalization of HMIT in the brain. (A) Immunostaining of astrocytes in the hippoccampus. (B) Immunodetection of HMIT in neurons of the cortex. (C) Immunoelectron microscopy detection of HMIT in an astrocytic endfoot near a blood vessel. Staining is both intracellular and associated with the plasma membrane (arrowheads). Magnification: 31 500×. Download figure Download PowerPoint Discussion Here we report the cloning and functional characterization of a novel HMIT. We show that this 12 TM domain transporter has unique structural characteristics and that it is mainly expressed in the brain, both in astrocytes and neurons. This suggests a participation in the control of several inositol-dependent mechanisms, including protection against osmotic shock, signalling pathways, vesicle endocytosis and exocytosis. HMIT has the same membrane topology as the glucose transporters GLUT1-5 and GLUTX1, and motifs described to be important for glucose transport activity are conserved. These include the GRR/K and EX6R/K motifs, which are found duplicated in the GLUTs, the QLS motif of TM7 and the tryptophan residues 388 and 412 (position within the GLUT1 sequence), which are present in the cytochalasin B binding site. Despite the presence of these sequences, no glucose transport activity could be demonstrated. Because HMIT presented sequence homologies with inositol transporters found in other species, transport of this substrate was evaluated. A very efficient myo-inositol uptake activity could be measured, which was stimulated by acidic pH. This acid-dependent activation was a result of an increase in Vmax, with no change in the affinity for myo-inositol, which was ∼100 μM at all pH values tested. This value is near the myo-inositol extracellular space co" @default.
• W2171937401 created "2016-06-24" @default.
• W2171937401 creator A5001478163 @default.
• W2171937401 creator A5034566439 @default.
• W2171937401 creator A5061532717 @default.
• W2171937401 creator A5071898730 @default.
• W2171937401 creator A5079729308 @default.
• W2171937401 creator A5084404570 @default.
• W2171937401 date "2001-08-15" @default.
• W2171937401 modified "2023-10-18" @default.
• W2171937401 title "Identification of a mammalian H+-myo-inositol symporter expressed predominantly in the brain" @default.
• W2171937401 cites W1524629686 @default.
• W2171937401 cites W1568192877 @default.
• W2171937401 cites W1614056212 @default.
• W2171937401 cites W1963136808 @default.
• W2171937401 cites W1965940344 @default.
• W2171937401 cites W1974642350 @default.
• W2171937401 cites W1981903107 @default.
• W2171937401 cites W1990708192 @default.
• W2171937401 cites W2003669697 @default.
• W2171937401 cites W2004972894 @default.
• W2171937401 cites W2005812409 @default.
• W2171937401 cites W2005865069 @default.
• W2171937401 cites W2007961360 @default.
• W2171937401 cites W2009008715 @default.
• W2171937401 cites W2011031456 @default.
• W2171937401 cites W2011666432 @default.
• W2171937401 cites W2013371301 @default.
• W2171937401 cites W2015750492 @default.
• W2171937401 cites W2015794252 @default.
• W2171937401 cites W2019968039 @default.
• W2171937401 cites W2023311065 @default.
• W2171937401 cites W2024256437 @default.
• W2171937401 cites W2044712342 @default.
• W2171937401 cites W2056597195 @default.
• W2171937401 cites W2058107898 @default.
• W2171937401 cites W2058390591 @default.
• W2171937401 cites W2068803610 @default.
• W2171937401 cites W2069282289 @default.
• W2171937401 cites W2080165775 @default.
• W2171937401 cites W2085968319 @default.
• W2171937401 cites W2116397048 @default.
• W2171937401 cites W2128960139 @default.
• W2171937401 cites W2134812217 @default.
• W2171937401 cites W2135152819 @default.
• W2171937401 cites W2140194302 @default.
• W2171937401 cites W2150418339 @default.
• W2171937401 cites W2150796852 @default.
• W2171937401 cites W2162163372 @default.
• W2171937401 cites W2176833444 @default.
• W2171937401 cites W2403008107 @default.
• W2171937401 doi "https://doi.org/10.1093/emboj/20.16.4467" @default.
• W2171937401 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/125574" @default.
• W2171937401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11500374" @default.
• W2171937401 hasPublicationYear "2001" @default.
• W2171937401 type Work @default.
• W2171937401 sameAs 2171937401 @default.
• W2171937401 citedByCount "206" @default.
• W2171937401 countsByYear W21719374012012 @default.
• W2171937401 countsByYear W21719374012013 @default.
• W2171937401 countsByYear W21719374012014 @default.
• W2171937401 countsByYear W21719374012015 @default.
• W2171937401 countsByYear W21719374012016 @default.
• W2171937401 countsByYear W21719374012017 @default.
• W2171937401 countsByYear W21719374012018 @default.
• W2171937401 countsByYear W21719374012019 @default.
• W2171937401 countsByYear W21719374012020 @default.
• W2171937401 countsByYear W21719374012021 @default.
• W2171937401 countsByYear W21719374012022 @default.
• W2171937401 countsByYear W21719374012023 @default.
• W2171937401 crossrefType "journal-article" @default.
• W2171937401 hasAuthorship W2171937401A5001478163 @default.
• W2171937401 hasAuthorship W2171937401A5034566439 @default.
• W2171937401 hasAuthorship W2171937401A5061532717 @default.
• W2171937401 hasAuthorship W2171937401A5071898730 @default.
• W2171937401 hasAuthorship W2171937401A5079729308 @default.
• W2171937401 hasAuthorship W2171937401A5084404570 @default.
• W2171937401 hasBestOaLocation W21719374012 @default.
• W2171937401 hasConcept C104317684 @default.
• W2171937401 hasConcept C116834253 @default.
• W2171937401 hasConcept C120405084 @default.
• W2171937401 hasConcept C149011108 @default.
• W2171937401 hasConcept C170493617 @default.
• W2171937401 hasConcept C2777427919 @default.
• W2171937401 hasConcept C54355233 @default.
• W2171937401 hasConcept C59822182 @default.
• W2171937401 hasConcept C70721500 @default.
• W2171937401 hasConcept C86803240 @default.
• W2171937401 hasConcept C95444343 @default.
• W2171937401 hasConceptScore W2171937401C104317684 @default.
• W2171937401 hasConceptScore W2171937401C116834253 @default.
• W2171937401 hasConceptScore W2171937401C120405084 @default.
• W2171937401 hasConceptScore W2171937401C149011108 @default.
• W2171937401 hasConceptScore W2171937401C170493617 @default.
• W2171937401 hasConceptScore W2171937401C2777427919 @default.
• W2171937401 hasConceptScore W2171937401C54355233 @default.
• W2171937401 hasConceptScore W2171937401C59822182 @default.
• W2171937401 hasConceptScore W2171937401C70721500 @default.

• next